1. P150 Once-daily tiotropium Respimat® reduces risk of severe asthma exacerbation and asthma worsening in symptomatic asthma, independent of allergic and inflammatory status. (12th November 2015) Authors: Dahl, R; Casale, T; Vandewalker, M; Schmidt, H; Engel, M; Moroni-Zentgraf, P; Kerstjens, HAM Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P154 Safety of tiotropium in pre-school children with symptomatic persistent asthma. (15th November 2016) Authors: Bisgaard, H; Vandewalker, M; Graham, L; Moroni-Zentgraf, P; Engel, M; Azzi, G El; Vulcu, SD; Finnigan, H; Vrijlandt, EJLE Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma. (15th November 2016) Authors: Vogelberg, C; Szefler, SJ; Hamelmann, E; Boner, A; Moroni-Zentgraf, P; Engel, M; Azzi, G El; Finnigan, H; Vandewalker, M Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P156 Efficacy, safety and tolerability of once-daily tiotropium respimat® add-on therapy in children with moderate symptomatic asthma. (15th November 2016) Authors: Schmidt, O; Hamelmann, E; Vogelberg, C; Laki, I; Azzi, G El; Engel, M; Moroni-Zentgraf, P; Finnigan, H; Vandewalker, M Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P163 Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status. (14th November 2013) Authors: Halpin, DMG; Bateman, ED; Tashkin, DP; Engel, M; Dahl, R; Paggiaro, P; Beck, E; Vandewalker, M; Seibold, W; Moroni-Zentgraf, P; Schmidt, H; Kerstjens, HAM Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P229 Once-daily Tiotropium Respimat® As Add-on To At Least Medium- To High-dose Ics, With Or Without Laba, Improves Lung Function In Patients With Symptomatic Asthma, Independent Of Allergic Status. (10th November 2014) Authors: Dahl, R; Casale, T; Pizzichini, E; Vandewalker, M; Virchow, JC; Engel, M; Sigmund, R; Moroni-Zentgraf, P; Kerstjens, HAM Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P231 Once-daily Tiotropium Respimat®: Safety And Tolerability Results From Five Phase Iii Trials In Adults With Symptomatic Asthma. (10th November 2014) Authors: Haughney, J; Vandewalker, M; Meltzer, E; Paggiaro, P; Engel, M; Unseld, A; Moroni-Zentgraf, P; Kerstjens, HAM Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S91 Once-daily tiotropium Respimat® add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma. (10th November 2014) Authors: Price, D; Engel, M; Moroni-Zentgraf, P; Schmidt, H; Dahl, R; Paggiaro, P; Vandewalker, M; Kerstjens, HAM; Kaplan, A Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗